Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer

针对剪接体的疗法可诱导三阴性乳腺癌产生抗病毒免疫反应

阅读:3
作者:Elizabeth A Bowling,Jarey H Wang,Fade Gong,William Wu,Nicholas J Neill,Ik Sun Kim,Siddhartha Tyagi,Mayra Orellana,Sarah J Kurley,Rocio Dominguez-Vidaña,Hsiang-Ching Chung,Tiffany Y-T Hsu,Julien Dubrulle,Alexander B Saltzman,Heyuan Li,Jitendra K Meena,Gino M Canlas,Srinivas Chamakuri,Swarnima Singh,Lukas M Simon,Calla M Olson,Lacey E Dobrolecki,Michael T Lewis,Bing Zhang,Ido Golding,Jeffrey M Rosen,Damian W Young,Anna Malovannaya,Fabio Stossi,George Miles,Matthew J Ellis,Lihua Yu,Silvia Buonamici,Charles Y Lin,Kristen L Karlin,Xiang H-F Zhang,Thomas F Westbrook

Abstract

Many oncogenic insults deregulate RNA splicing, often leading to hypersensitivity of tumors to spliceosome-targeted therapies (STTs). However, the mechanisms by which STTs selectively kill cancers remain largely unknown. Herein, we discover that mis-spliced RNA itself is a molecular trigger for tumor killing through viral mimicry. In MYC-driven triple-negative breast cancer, STTs cause widespread cytoplasmic accumulation of mis-spliced mRNAs, many of which form double-stranded structures. Double-stranded RNA (dsRNA)-binding proteins recognize these endogenous dsRNAs, triggering antiviral signaling and extrinsic apoptosis. In immune-competent models of breast cancer, STTs cause tumor cell-intrinsic antiviral signaling, downstream adaptive immune signaling, and tumor cell death. Furthermore, RNA mis-splicing in human breast cancers correlates with innate and adaptive immune signatures, especially in MYC-amplified tumors that are typically immune cold. These findings indicate that dsRNA-sensing pathways respond to global aberrations of RNA splicing in cancer and provoke the hypothesis that STTs may provide unexplored strategies to activate anti-tumor immune pathways.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。